Carlyle in Talks To Buy Pharmaceutical Product Development Inc.

Private-equity Carlyle Group is in talks to acquire Pharmaceutical Product Development Inc., media reports said Monday, quoting people familiar with the matter.

Carlyle Group edged out other private-equities such as Blackstone Group, KKR & Co., and Hellman & Friedman that evinced interest in the clinical research company. Most bids were between $33 and $38 a share, or as much as $4.3 billion.
Carlyle is also said to be in talks with other private-equity firms regarding involvement in the acquisition of North Carolina-based Pharmaceutical Product Development Inc.

For Carlyle, the purchase of Pharmaceutical Product Development Inc. would be its largest since announcing the $3.9 billion wrap-up of CommScope Inc. in October. Separately, Carlyle today said it will sell Insight Communications Co. to Time Warner Cable Inc. for about $3.0 billion.

Pharmaceutical Product Development Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. Last month, the company said its second quarter profit surged to $46.51 million or $0.41 per share from $20.98 million or $0.18 per share last year. Quarterly sales jumped to $407.70 million from $369.92 million.

 

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.